-
Jan 22, 2025 | 
ballardspahr.com | Margaret Bolce Brivanlou |Peter A. Jaslow |Philip Legendy |Scott D. Marty
Ballard Spahr attorneys from the firm’s Life Sciences and Health Care Industry Teams were on the ground in sunny San Francisco for the 43rd Annual J.P. Morgan Health Care Conference (#JPM25) January 12-15. The weather was vibrant and so was the atmosphere, with ample opportunity for networking and collaboration among prominent participants. KEY TAKEAWAYS: Cautious Optimism for Deal Making.
-
Jan 6, 2025 | 
law360.co.uk | Ryan Udell |Scott D. Marty |Harry Levin
ADVERTISEMENT Don't want ads? Subscribe or login now. By Ryan Udell, Scott Marty and Harry Levin ( January 6, 2025, 4:44 PM EST) -- With the start of the new year, we look back at some of the significant trends influencing intellectual property licensing in 2024. These themes highlight key considerations for navigating the evolving landscape of IP licensing....
-
Oct 29, 2024 | 
jdsupra.com | Harry Levin |Scott D. Marty |Ryan Udell
The Licensing Executives Society (LES) recently held its annual meeting in New Orleans, drawing together a diverse group of intellectual property (IP) licensing professionals, including attorneys, academics, service providers, and industry leaders in fields like life sciences and high technology. The multi-day event covered a range of important themes for those navigating the evolving landscape of IP licensing. Our team was excited to be on the ground. Here are the main takeaways:1.
-
Jan 18, 2024 | 
ballardspahr.com | Scott D. Marty |Ryan Udell |Philip Legendy
Ballard Spahr attorneys from the firm’s Life Sciences and Health Care Industry Teams were on the ground for the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) from January 7-10. While still less crowded than pre-pandemic levels, there was a general air of optimism that had been missing last year and the discussions were as compelling as ever at the premier gathering of global industry leaders, emerging companies, technology creators, and the investment community.
-
Jul 21, 2023 | 
jdsupra.com | Scott D. Marty |Ryan Udell
The Inflation Reduction Act (IRA), signed into law in August 2022, impacted a wide range of tax laws and touched many aspects of government. Significantly, part of the IRA provides Medicare with the ability to negotiate the prices of certain high-cost, qualifying single-source drugs. For the consumer, this means that Medicare will be able to negotiate directly with drug companies to lower the price of some of the most expensive Medicare Part D drugs.
-
Jul 19, 2023 | 
law360.com | Scott D. Marty |William Rhodes |Catherine Seibel
By Scott Marty, William Rhodes and Catherine Seibel (July 19, 2023, 4:57 PM EDT) -- The life sciences industry may face a significant shift in the coming years in how research is funded and conducted due to a coalescence of factors within the industry and the broader economy.... Law360 is on it, so you are, too. A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence.
-
Jul 19, 2023 | 
ballardspahr.com | Scott D. Marty |William Rhodes |Catherine Seibel
A number of factors have led some industry participants and analysts to predict that the time is approaching when big pharma will not be generating the same level of new research and technology as in the recent past. So where can the life sciences industry look to find new research and technology? The answer may lie in a growing trend of partnerships with the education industry in the form of accelerators, incubator programs, and sponsored research.
-
May 23, 2023 | 
jdsupra.com | Caryn Borg-Breen |Scott D. Marty |Margaret Brivanlou Ph.D
On May 18, 2023, the Supreme Court decided Amgen Inc., et al. v. Sanofi, et al., No. 2-1757, unanimously affirming decisions of the Federal Circuit and the District of Delaware finding for respondents Sanofi and Regeneron that petitioner Amgen’s patent claims directed to a genus of antibodies are invalid for lack of enablement under 35 U.S.C. § 112(a). According to the Court, Amgen’s patent claims did not describe the full scope of the antibody genus according to its structure.
-
May 22, 2023 | 
ballardspahr.com | Caryn Borg-Breen |Scott D. Marty |Margaret Bolce Brivanlou |Kenneth H. Sonnenfeld
Summary In Amgen v. Sanofi, the Supreme Court unanimously affirmed the District of Delaware and Federal Circuit findings that Amgen’s functionally defined patent claims to a class of therapeutic antibodies are invalid as lacking enablement in the specification. The decision has implications for procurement and enforcement of patents to biotechnology inventions.
-
Jan 24, 2023 | 
jdsupra.com | Scott D. Marty |Ryan Udell
The 41st Annual JP Morgan Healthcare Conference in rainy San Francisco earlier this month was relatively low-key compared to pre-pandemic versions of the health care investment symposium, which returned this year from an in-person hiatus. The discussions and activity were as compelling as ever at the gathering of global industry leaders, emerging companies, technology creators, and the investment community.
